Aptinyx (NASDAQ:APTX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Aptinyx (NASDAQ:APTX – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.02, Fidelity Earnings reports. During the same quarter in the prior year, the company earned ($0.22) EPS.

Shares of APTX stock traded up $0.10 during trading on Friday, reaching $0.70. The company’s stock had a trading volume of 136,370 shares, compared to its average volume of 312,910. The company has a quick ratio of 20.18, a current ratio of 20.18 and a debt-to-equity ratio of 0.15. The business has a fifty day moving average price of $1.78 and a 200-day moving average price of $2.43. Aptinyx has a one year low of $0.57 and a one year high of $4.73. The company has a market cap of $47.40 million, a price-to-earnings ratio of -0.59 and a beta of 1.46.

APTX has been the subject of several analyst reports. BMO Capital Markets cut their price target on shares of Aptinyx from $12.00 to $6.00 in a report on Friday, April 8th. SVB Leerink dropped their target price on shares of Aptinyx from $10.00 to $4.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Zacks Investment Research downgraded shares of Aptinyx from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Truist Financial dropped their target price on shares of Aptinyx from $12.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, April 8th. Finally, William Blair downgraded shares of Aptinyx from an “outperform” rating to a “market perform” rating in a research note on Thursday, April 7th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $3.88.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP raised its position in Aptinyx by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 123,937 shares of the company’s stock worth $331,000 after acquiring an additional 6,133 shares in the last quarter. Royal Bank of Canada raised its position in shares of Aptinyx by 244.5% in the second quarter. Royal Bank of Canada now owns 9,288 shares of the company’s stock valued at $26,000 after purchasing an additional 6,592 shares during the period. Charles Schwab Investment Management Inc. bought a new position in shares of Aptinyx in the fourth quarter valued at about $54,000. BlackRock Inc. raised its position in shares of Aptinyx by 1.5% in the fourth quarter. BlackRock Inc. now owns 1,374,768 shares of the company’s stock valued at $3,669,000 after purchasing an additional 20,928 shares during the period. Finally, Cetera Advisor Networks LLC bought a new position in shares of Aptinyx in the first quarter valued at about $92,000. 55.97% of the stock is currently owned by hedge funds and other institutional investors.

Aptinyx Company Profile (Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Featured Articles